Browse All

Current Filters

CLEAR FILTER x

TITLE

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

Author:Cohen, Jeffrey   Hauser, Stephen   Zielman, Ronald   Das Gupta, Ayan   Azmon, Amin   Xi, Jing   Mavrikis Cox, Gina   Robertson, Derrick   Wiendl, Heinz   Kappos, Ludwig   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.009  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA, San Francisco, CA  Central Texas Neurology Consultants, Round Rock, TX, USA, Round Rock, TX  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma A.G., Basel, Switzerland, Basel, Switzerland  China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, Shanghai, China, People's Republic of  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  University of Muenster, Muenster, Germany, Muenster, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial